Choroidal neovascularization associated with adult‐onset vitelliform dystrophy treated with intravitreal ranibizumab

• Published in: Acta ophthalmologica (Oxford, England) Vol. 88; no. s246
• Main Authors: PRIETO CALVO, E, EGEA ESTOPINAN, C, GUERRI MONCLUS, N, TORRÓN FERNÁNDEZ‐BLANCO, C, IDOIPE CORTA, M
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-09-2010
• ISSN: 1755-375X; 1755-3768
• DOI: 10.1111/j.1755-3768.2010.274.x

Purpose Adult‐onset foveomacular dystrophy (AFVD) is a hereditary ocular condition, which results in the presence of slightly elevated and yellowish subretinal macular lesions, similar to those of Best’s disease, but smaller than these. Usually, these patients have a fair visual prognosis if there are no complications in the clinical course of the disease. We report a case describing a patient affected with occult choroidal neovascularization (CNV) associated with AFVD, who underwent treatment with intravitreal ranibizumab.
Methods Prospective, interventional, single case report. A 70‐year‐old male patient diagnosed with bilateral adult‐onset vitelliform dystrophy, presents a sudden decrease of vision in his left eye (LE) associated with a subretinal haemorrhage and serous detachment in the macular area, on fundus examination. Fluorescein angiography in the LE confirmed the presence of an occult choroidal neovascular membrane. Intravitreal ranibizumab was performed because of the juxtafoveal localization of the CNV.
Results Two consecutive injections were needed to induce total regression of the lesion. Six months after the last injection, visual acuity remained stable at 7/10 with no recurrence as evaluated by fundus biomicroscopy and optical coherence tomography (OCT).
Conclusion Intravitreal ranibizumab has shown a satisfactory morphological and functional improvement in this case of CNV associated with adult‐onset vitelliform dystrophy. Further case series are required to confirm this observation.